XNAS · Biotechnology
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$120.00-3.21%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
52/100
Moderate
Score components
TickerWhale View
Insmed scores 52 out of 100 overall, which we rate moderate. Quality & growth is its strongest area and Risk its weakest.
What helps
- Quality & growth
- Valuation
- Sentiment Signal
What to watch
- Technical
- Risk
Quality & growth
30%69Positive
- Revenue growth 185.8%
- EPS growth n/a
Valuation
25%58Positive
- P/E -29.8
- EV/Sales 22.9
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
#389 by market cap in our coverage · ~1,664 employees · Listed 2000-06-01 · www.insmed.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#87 / 139sector rank by TickerWhale Score
TickerWhale Score 52 vs sector average 55.1 (-3.1)
Revenue growth (industry)Top 11%
Gross margin (industry)Top 63%
Return on equity (industry)Top 91%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
36/100Weak vs universe
Ranks 36th of 100 covered names on our technical composite — the composite itself scores 40/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
2 buy · 3 sell · 3 neutral of 8 votes
TickerWhale rates INSM's technical setup weak — 36th percentile of the covered universe. Classic chart indicators lean sell, pointing the same way.
Moving averages
2 / 9constructive
- vs 200-day-12.5%
- vs 50-day+1.5%
Momentum
Mixed
- RSI (14)46 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rbuy
Trend
Mixed
- ADX (14) trend strength13· weak trend
- MACD (12,26,9)sell(histogram -1.016)
How the classic verdict is reached
Moving averages (9) agree on sell — 2 buy vs 6 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 2 sell · 3 neutral.
Result — 2 buy vs 3 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)-29.8 · TTM loss
- P/S (TTM)22.9
- P/B34.4
- EV/EBITDA—
- EV/Sales22.9
- PEG—
Profitability & returns
- Gross margin83.5%
- Net margin-76.9%
- ROE-119.7%
- Debt/Equity0.75
Growth
- Revenue growth (YoY)185.8%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $26.1B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INSMCurrentInsmed | 52 | 40 | -29.8 | — | 34.4 | 22.9 | $120.00 | -3.21% | +185.8% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.